Results 161 to 170 of about 94,964 (227)

Study on the Binding of Five Plant-Derived Secondary Metabolites to G‑Quadruplexes. [PDF]

ACS Omega
Vrtalová L, Dobrovolná M, Platero-Rochart D, Ptaszek AL, Brázda V, Sánchez-Murcia PA.   +5 more
europepmc   +1 more source

Incorporating Scale Uncertainty into Differential Expression Analyses Using ALDEx2

Current Protocols, Volume 6, Issue 2, February 2026.
Abstract Differential abundance or expression analyses are routinely performed on metagenomic, metatranscriptomic, and amplicon sequencing data. In such datasets, analysts usually have no information regarding the true scale (i.e., size) of the microbial community or sample under study, with inter‐sample differences in sequencing depth instead being ...
Scott J. Dos Santos, Gregory B. Gloor
wiley   +1 more source

Optimizing Liquid Biopsy: Spike-In Panel Approach for ctDNA Copy Number Variation Analysis. [PDF]

Cancer Genomics Proteomics
Kim H, Kim BM, Kim J, Seo SH, Hwang SM, Park KU.   +5 more
europepmc   +1 more source

Targeting aerobic glycolysis combats tyrosine kinase inhibitor resistance of hepatocellular carcinoma

International Journal of Cancer, Volume 158, Issue 3, Page 475-487, 1 February 2026.
Abstract Hepatocellular carcinoma (HCC) represents the predominant form of primary liver cancer and is frequently identified at a late stage, necessitating systemic therapy. However, resistance to first‐line tyrosine kinase inhibitor therapies, such as sorafenib and lenvatinib, remains a significant clinical challenge.
Longtao Zhao, Junjie Cheng, Yiming Zheng, Jing Wu, Jia Fan, Haixiang Sun, Chao Gao   +6 more
wiley   +1 more source

VRK2 targeting potentiates anti-PD-1 immunotherapy in hepatocellular carcinoma through MYC destabilization. [PDF]

Nat Commun
Su C, Liao Z, Mo J, Liu F, Wang W, Zhang H, Zhang H, Liu Y, Pan Y, Zhu H, Chen X, Zhang Z, Zhu P, Zhang B.   +13 more
europepmc   +1 more source

Loss of METTL3 m6A methyltransferase results in short‐term progression and poor treatment outcome of bladder cancer patients

International Journal of Cancer, Volume 158, Issue 3, Page 763-774, 1 February 2026.
What's new? Bladder cancer exhibits a highly heterogeneous molecular landscape and treatment response. The dysregulation of RNA modifications such as m6A has been involved in cancer initiation and progression. This study comprehensively analyzed the expression of the main catalytic component of the m6A methylation machinery in bladder tumors across one
Katerina‐Marina Pilala, Stella Koroneou, Maria‐Alexandra Papadimitriou, Konstantina Panoutsopoulou, Konstantinos Soureas, Georgios‐Christos Giagkos, Panagiotis Levis, Dimitrios Linardoutsos, Konstantinos Stravodimos, Margaritis Avgeris, Andreas Scorilas   +10 more
wiley   +1 more source

In vivo inhibition of c-MYC in the metastatic drug-resistant ovarian cancer cells down regulates the c-MYC-PD-L1-PAX8-p21 to achieve therapeutic efficacy. [PDF]

BMC Cancer
Chen Q, Dorji JP, Perera SG, Li P, Aijaz F, Ihuoma LC, Matsui H, Awah CU.   +7 more
europepmc   +1 more source

A Dually Nanobody‐Engineered Milk‐Derived Extracellular Vesicle Nanomedicine Targeting Tumour‐Associated Macrophages and Cancer Cells for Cancer Therapy

Journal of Extracellular Vesicles, Volume 15, Issue 2, February 2026.
ABSTRACT Tumour development and progression are driven by intricate interactions among various cell types within the tumour microenvironment (TME). Targeting a single cell type often fails to eradicate cancer, highlighting the need for strategies to co‐target multiple cell types.
Zhiang Liu, Ying Chen, Yulin Cao, Yanchao Zhang, Yuanben Wang, Han Cheng, Junhui Tang, Haofei Hong, Yuyang Feng, Surui Yao, Zehua Bian, Yuan Yin, Kaisa Cui, Zhimeng Wu, Zhaohui Huang   +14 more
wiley   +1 more source

Elucidating the Role of <i>CNOT2</i> in Regulating Cancer Cell Growth via the Modulation of p53 and c-Myc Expression. [PDF]

Curr Issues Mol Biol
Lee J, Kim JH, Lee YJ, Oh JJ, Han YJ, Jung JH.   +5 more
europepmc   +1 more source

Alterations in Gut Microbiota and Metabolic Profiles in Relapsed or Refractory Lymphoma

MicrobiologyOpen, Volume 15, Issue 1, February 2026.
Metabolomic volcano‐heatmap reveals seven upregulated metabolites in relapsed/refractory lymphoma, underscoring gut metabolic reprogramming as a potential therapeutic target. ABSTRACT To identify potential therapeutic strategies for relapsed or refractory lymphoma (R/RL) by examining differences in gut microbiota composition and metabolic profiles ...
Yu‐Ying Guo, Kang‐Jing Xue, Liao Wang, Gang‐Gang Wang, Ting‐Ting Zhang, Shu‐Ling Hou   +5 more
wiley   +1 more source